The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of ≥ 12 weeks at enrolment.
Adequate organ and marrow function.
Minimum body weight > 30 kg.
Active or prior documented autoimmune disease requiring systemic treatment.
Uncontrolled infection (including human immunodeficiency virus [HIV], hepatitis B or C).
Prior exposure to immune checkpoint inhibitors.
Mixed SCLC and NSCLC histology.